Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

This is not a treatment trial — it is a testing service for people who previously received a specific type of gene therapy made by Bristol-Myers Squibb (BMS) and have now been diagnosed with a new, separate cancer. The program tests tumor samples to investigate whether the gene therapy may be linked to the new cancer. **You may be eligible if...** - You previously received a BMS-manufactured gene-modified cell therapy (such as a CAR-T therapy) - You have since been diagnosed with a new primary cancer (a second, unrelated cancer) - BMS has determined your new cancer qualifies for investigation - You are not already enrolled in another clinical trial that covers this type of testing **You may NOT be eligible if...** - You are currently in another clinical trial that already includes this tumor testing - Your new cancer has not been identified by BMS as qualifying for this program Talk to your doctor to see if this trial is right for you.